EMA committee recommends drug candidate from Ascendis Pharma
In the US, the FDA rejected the drug candidate TransCon PTH in May, but in Europe, the path now seems clear for the Danish-American biotech company’s hypoparathyroidism drug to be approved.
The European Medicines Agency’s (EMA) advisory panel, CHMP, recommends approval of drug candidate TransCon PTH (palopegteriparatide), developed by Danish-American biotech company Ascendis Pharma, the company writes in an announcement on Friday morning.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
FDA points out shortcomings in Ascendis application
For subscribers
